A5021579716- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Mesenchymal stem cell research
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Cancer Research and Treatments
- Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Pluripotent Stem Cells Research
- RNA Interference and Gene Delivery
- Muscle Physiology and Disorders
- Histone Deacetylase Inhibitors Research
- Cancer Cells and Metastasis
- Ubiquitin and proteasome pathways
- Monoclonal and Polyclonal Antibodies Research
- Neonatal Respiratory Health Research
- CRISPR and Genetic Engineering
- Cancer Immunotherapy and Biomarkers
University of California, Davis
2016-2025
UC Davis Comprehensive Cancer Center
2014-2025
University of California Davis Medical Center
2012-2024
University College London
2024
University Hospitals Birmingham NHS Foundation Trust
2024
University Hospitals Bristol NHS Foundation Trust
2024
Cambridge University Hospitals NHS Foundation Trust
2024
University College London Hospitals NHS Foundation Trust
2024
Newcastle upon Tyne Hospitals NHS Foundation Trust
2024
King's College Hospital NHS Foundation Trust
2024
Abstract Bone marrow has long been known to be a source of stem cells capable regeneration the hematopoeitic system. Recent reports, however, have indicated that bone might also contain early can differentiate into other organ tissues such as skin. While these studies illustrated could find their way skin, they not addressed dynamics how participate in homeostatis and In this report we followed green fluorescent protein (GFP) labeled transplanted non‐GFP mice order determine participation...
BACKGROUND Chimeric antigen receptor (CAR)‐modified “designer” T cells (dTc, CAR‐T) against PSMA selectively target antigen‐expressing in vitro and eliminate tumors vivo. Interleukin 2 (IL2), widely used adoptive therapies, was proven essential animal models for dTc to eradicate established solid tumors. METHODS Patients underwent chemotherapy conditioning, followed by dosing under a Phase I escalation with continuous infusion low dose IL2 (LDI). A of achieve ≥20% engraftment infused...
Abstract T cell receptors (TCRs) enable cells to specifically recognize mutations in cancer 1–3 . Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision genome-editing simultaneously knockout the two endogenous TCR genes TRAC (which encodes TCRα) and TRBC TCRβ). We also inserted into locus chains of neoantigen-specific (neoTCR) isolated from circulating patients. The neoTCRs were using personalized library soluble predicted neoantigen–HLA capture reagents....
Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses intermediate-affinity CAR to reduce toxic effects and improve persistence. We conducted a phase 1b-2 multicenter study of obe-cel in adults (≥18 years age) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The main cohort, cohort 2A, included patients morphologic disease; 2B had measurable residual disease. primary end point was overall remission...
Purpose.: Because human bone marrow (BM) CD34+ stem cells home into damaged tissue and may play an important role in repair, this pilot clinical trial explored the safety feasibility of intravitreal autologous BM as potential therapy for ischemic or degenerative retinal conditions. Methods.: This prospective study enrolled six subjects (six eyes) with irreversible vision loss from vascular occlusion, hereditary nonexudative age-related macular degeneration, retinitis pigmentosa. were...
Duchenne muscular dystrophy (DMD) is caused by mutations in dystrophin and the subsequent disruption of dystrophin-associated protein complex (DAPC). Utrophin a homolog expressed at high levels developing muscle that an attractive target for DMD therapy. Here we show extracellular matrix biglycan regulates utrophin expression immature recombinant human (rhBGN) increases cultured myotubes. Systemically delivered rhBGN up-regulates sarcolemma reduces pathology mdx mouse model DMD. RhBGN...
Abstract Background Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) based on ZUMA-3 study results. We report updated outcomes longer follow-up and extended data set along contextualization of historical standard care. Methods Adults R/R B-ALL received a single infusion KTE-X19 (1 × 10 6 T cells/kg). Long-term post hoc subgroup...
Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 CAR T-cell therapy approved in the US to treat adults aged ≥18 years (≥26 EU) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Brexu-cel showed overall complete remission (CR)/CR incomplete hematologic recovery (CRi) rate of 73% (CR 60%) and median survival (OS) 25.4 months 78 patients R/R B-ALL after 2 ZUMA-3. Here, we report updated outcomes >3 follow-up. As July 23, 2022, follow-up all (N = 78) was...
ABSTRACT HIV gene therapy has the potential to offer an alternative use of current small-molecule antiretroviral drugs as a treatment strategy for HIV-infected individuals. Therapies designed administer HIV-resistant stem cells infected patient may also provide functional cure, observed in bone marrow transplant performed with hematopoietic (HSCs) homozygous CCR5-Δ32-bp allele. In our studies, preclinical evaluation combination anti-HIV lentiviral vector was performed, vivo , humanized...
Summary This phase II study evaluated the safety and efficacy of lenalidomide in combination with rituximab patients relapsed/refractory, indolent non‐ H odgkin lymphoma ( NHL ). Patients were treated daily 28‐d cycles weekly for 4 weeks. Lenalidomide was continued until progression or unacceptable toxicity. Twenty‐two assessed FCGR 3 A polymorphisms. Thirty enrolled; 27 evaluable response. The overall response rate ORR ) 74% including 44% complete responses CR ); median progression‐free...
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with poor prognosis and represents major unmet medical need. We report on real-world academic center experience of treating 25 patients relapsed/refractory AML using venetoclax in combination decitabine or azacitidine, which not otherwise widely evaluated the current literature. Our come from large, socioeconomically geographically diverse area including majority Northern California. Most had ELN Adverse Risk (52%)...
Abstract Background Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing Aivita GBM vaccine (AV-GBM-1), (2) Adverse Events (AE) associated with AV-GBM-1 administration, and (3) survival. Methods Fresh suspected glioblastoma tissue collected during surgery, patients pathology-confirmed enrolled before starting concurrent Radiation Therapy Temozolomide (RT/TMZ) Intent Treat (ITT) after...
Background Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and European Union patients ≥26 years R/R B-ALL. After 2 of follow-up ZUMA-3, overall complete remission (CR) rate (CR+CR incomplete hematological recovery (CRi)) was 73%, median survival (OS) 25.4 months 78 Phase 1 B-ALL who received pivotal dose brexu-cel....
6504 Background: Obe-cel is an autologous CAR-T cell product with a fast off-rate CD19 binder designed to mitigate immunotoxicity and improve expansion/persistence. Pooled results from the pivotal FELIX phase Ib/II study (NCT04404660) of obe-cel in adults R/R B-ALL were recently presented (Roddie C et al. Blood 2023;142[Suppl 1]:222). Here, OS EFS all patients (pts) treated are reported, alongside impact persistency consolidative SCT for pts remission. Methods: Pts aged ≥18 yrs enrolled....
The efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by acute and chronic graft-versus-host disease (GVHD). impact obesity on allo-HSCT outcomes poorly understood. Here, we report that had a negative selective gut GVHD after in mice with diet-induced (DIO). These animals exhibited increased permeability, endotoxin translocation across the gut, radiation-induced gastrointestinal damage allo-HSCT. After allo-HSCT, both male female DIO mouse recipients...